Found 25 results
Filters: First Letter Of Last Name is M  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
M
Genome-wide analysis of DNA binding and transcriptional regulation by the mammalian Doublesex homolog DMRT1 in the juvenile testis., Murphy, Mark W., Sarver Aaron L., Rice Daren, Hatzi Katerina, Ye Kenny, Melnick Ari, Heckert Leslie L., Zarkower David, and Bardwell Vivian J. , Proc Natl Acad Sci U S A, 2010 Jul 27, Volume 107, Issue 30, p.13360-5, (2010)
Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90., Moulick, Kamalika, Ahn James H., Zong Hongliang, Rodina Anna, Cerchietti Leandro, DaGama Erica M. Gomes, Caldas-Lopes Eloisi, Beebe Kristin, Perna Fabiana, Hatzi Katerina, et al. , Nat Chem Biol, 2011 Sep 25, Volume 7, Issue 11, p.818-26, (2011)
Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation., Moran-Crusio, Kelly, Reavie Linsey, Shih Alan, Abdel-Wahab Omar, Ndiaye-Lobry Delphine, Lobry Camille, Figueroa Maria E., Vasanthakumar Aparna, Patel Jay, Zhao Xinyang, et al. , Cancer Cell, 2011 Jul 12, Volume 20, Issue 1, p.11-24, (2011)
Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma., Mondello, Patrizia, Tadros Saber, Teater Matt, Fontan Lorena, Chang Aaron Y., Jain Neeraj, Yang Haopeng, Singh Shailbala, Ying Hsia-Yuan, Chu Chi-Shuen, et al. , Cancer Discov, 2020 Mar, Volume 10, Issue 3, p.440-459, (2020)
Germinal center-derived lymphomas: The darkest side of humoral immunity., Mlynarczyk, Coraline, Fontan Lorena, and Melnick Ari , Immunol Rev, 2019 Mar, Volume 288, Issue 1, p.214-239, (2019)
DNMT3A Haploinsufficiency Transforms FLT3ITD Myeloproliferative Disease into a Rapid, Spontaneous, and Fully Penetrant Acute Myeloid Leukemia., Meyer, Sara E., Qin Tingting, Muench David E., Masuda Kohei, Venkatasubramanian Meenakshi, Orr Emily, Suarez Lauren, Gore Steven D., Delwel Ruud, Paietta Elisabeth, et al. , Cancer Discov, 2016 05, Volume 6, Issue 5, p.501-15, (2016)
CtBP is an essential corepressor for BCL6 autoregulation., Mendez, Lourdes M., Polo Jose M., J Yu Jessica, Krupski Melissa, B Ding Belinda, Melnick Ari, and B Ye Hilda , Mol Cell Biol, 2008 Apr, Volume 28, Issue 7, p.2175-86, (2008)
Clonal Hematopoiesis Before, During, and After Human Spaceflight., Mencia-Trinchant, Nuria, MacKay Matthew J., Chin Christopher, Afshinnekoo Ebrahim, Foox Jonathan, Meydan Cem, Butler Daniel, Mozsary Christopher, Vernice Nicholas A., Darby Charlotte, et al. , Cell Rep, 2020 Dec 08, Volume 33, Issue 10, p.108458, (2020)
Identification of novel chromosomal rearrangements in acute myelogenous leukemia involving loci on chromosome 2p23, 15q22 and 17q21., Melnick, A, Fruchtman S, Zelent A, Liu M, Huang Q, Boczkowska B, Calasanz M, Fernandez A, Licht J D., and Najfeld V , Leukemia, 1999 Oct, Volume 13, Issue 10, p.1534-8, (1999)
The theoretical basis of transcriptional therapy of cancer: can it be put into practice?, Melnick, Ari M., Adelson Kerin, and Licht Jonathan D. , J Clin Oncol, 2005 Jun 10, Volume 23, Issue 17, p.3957-70, (2005)
The ETO protein disrupted in t(8;21)-associated acute myeloid leukemia is a corepressor for the promyelocytic leukemia zinc finger protein., Melnick, A M., Westendorf J J., Polinger A, Carlile G W., Arai S, Ball H J., Lutterbach B, Hiebert S W., and Licht J D. , Mol Cell Biol, 2000 Mar, Volume 20, Issue 6, p.2075-86, (2000)
Reprogramming specific gene expression pathways in B-cell lymphomas., Melnick, Ari , Cell Cycle, 2005 Feb, Volume 4, Issue 2, p.239-41, (2005)
Epigenetics in AML., Melnick, Ari M. , Best Pract Res Clin Haematol, 2010 Dec, Volume 23, Issue 4, p.463-8, (2010)
In-depth mutational analysis of the promyelocytic leukemia zinc finger BTB/POZ domain reveals motifs and residues required for biological and transcriptional functions., Melnick, A, Ahmad K F., Arai S, Polinger A, Ball H, Borden K L., Carlile G W., Prive G G., and Licht J D. , Mol Cell Biol, 2000 Sep, Volume 20, Issue 17, p.6550-67, (2000)
Histone deacetylases as therapeutic targets in hematologic malignancies., Melnick, Ari, and Licht Jonathan D. , Curr Opin Hematol, 2002 Jul, Volume 9, Issue 4, p.322-32, (2002)
AML-1/ETO fusion protein is a dominant negative inhibitor of transcriptional repression by the promyelocytic leukemia zinc finger protein., Melnick, A, Carlile G W., McConnell M J., Polinger A, Hiebert S W., and Licht J D. , Blood, 2000 Dec 01, Volume 96, Issue 12, p.3939-47, (2000)
Critical residues within the BTB domain of PLZF and Bcl-6 modulate interaction with corepressors., Melnick, Ari, Carlile Graeme, K Ahmad Farid, Kiang Chih-Li, Corcoran Connie, Bardwell Vivian, Prive Gilbert G., and Licht Jonathan D. , Mol Cell Biol, 2002 Mar, Volume 22, Issue 6, p.1804-18, (2002)
Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia., Melnick, A, and Licht J D. , Blood, 1999 May 15, Volume 93, Issue 10, p.3167-215, (1999)
Transitioning from fellowship to a physician-scientist career track., Melnick, Ari , Hematology Am Soc Hematol Educ Program, 2008, p.16-22, (2008)
Spotlight on acute promyelocytic leukemia: controversies and challenges., Melnick, A , Leukemia, 2002 Oct, Volume 16, Issue 10, p.1893-5, (2002)
Epigenetic therapy leaps ahead with specific targeting of EZH2., Melnick, Ari , Cancer Cell, 2012 Nov 13, Volume 22, Issue 5, p.569-70, (2012)
Mechanistic rationale for targeting the unfolded protein response in pre-B acute lymphoblastic leukemia., Masouleh, Behzad Kharabi, Geng Huimin, Hurtz Christian, Chan Lai N., Logan Aaron C., Chang Mi Sook, Huang ChuanXin, Swaminathan Srividya, Sun Haibo, Paietta Elisabeth, et al. , Proc Natl Acad Sci U S A, 2014 May 27, Volume 111, Issue 21, p.E2219-28, (2014)
Outcome of deferred initial therapy in mantle-cell lymphoma., Martin, Peter, Chadburn Amy, Christos Paul, Weil Karen, Furman Richard R., Ruan Jia, Elstrom Rebecca, Niesvizky Ruben, Ely Scott, Diliberto Maurizio, et al. , J Clin Oncol, 2009 Mar 10, Volume 27, Issue 8, p.1209-13, (2009)
ORY-1001, a Potent and Selective Covalent KDM1A Inhibitor, for the Treatment of Acute Leukemia., Maes, Tamara, Mascaró Cristina, Tirapu Iñigo, Estiarte Angels, Ciceri Filippo, Lunardi Serena, Guibourt Nathalie, Perdones Alvaro, Lufino Michele M. P., Somervaille Tim C. P., et al. , Cancer Cell, 2018 Mar 12, Volume 33, Issue 3, p.495-511.e12, (2018)
The therapeutic landscape for cells engineered with chimeric antigen receptors., MacKay, Matthew, Afshinnekoo Ebrahim, Rub Jonathan, Hassan Ciaran, Khunte Mihir, Baskaran Nithyashri, Owens Bryan, Liu Lauren, Roboz Gail J., Guzman Monica L., et al. , Nat Biotechnol, 2020 Feb, Volume 38, Issue 2, p.233-244, (2020)